PMA device
Portico Heart Valve, FlexNav Delivery System, FlexNav Loading System
Abbott Medical · Aortic Valve, Prosthesis, Percutaneously Delivered (NPT, Class III) · First FDA decision Sep 17, 2021, newest Nov 12, 2021Aortic stenosis
Last checked: Nov 20, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
2
PMA pathway
Device trials
12
Naming "Portico"
MAUDE reports
518
Brand "Portico", since 2015
PubMed studies
175
Mentioning "Portico"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing Portico Heart Valve, FlexNav Delivery System, FlexNav Loading System
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 2 of 2 decisions filed under this name.
P190023-S001 · Decided Nov 12, 2021 · 28 days after receipt · Normal 180 Day Track No User Fee
Device type: Aortic valve, prosthesis, percutaneously delivered (NPT) · Cardiology
P190023 · Decided Sep 17, 2021 · 739 days after receipt
Device type: Aortic valve, prosthesis, percutaneously delivered (NPT) · Cardiology
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
- Transcatheter Aortic Valve Replacement (TAVR)National analysisReview closedCAG-00430RUpdated Sep 23, 2026
- Transcatheter Aortic Valve Replacement (TAVR)National analysisReview closedCAG-00430NUpdated Sep 23, 2026
- Transcatheter Aortic Valve Replacement (TAVR) for Aortic Regurgitation (AR)National analysisUnder reviewCAG-00430R3Updated Sep 14, 2026
- Transcatheter Aortic Valve Replacement (TAVR)National analysisReview closedCAG-00430R2Updated Sep 10, 2026
- Transcatheter Aortic Valve Replacement (TAVR)National determinationOn the books20.32Updated Aug 16, 2023
Clinical trials
Device studies on ClinicalTrials.gov that name "Portico", any status and sponsor, newest update first.
- Portico Next Generation Approval StudyActive, not recruiting
Abbott Medical DevicesPublic (ABT)
NCT04011722 · 333 participants · Start Sep 17, 2019 · Primary completion Jan 12, 2023
Device: Portico™ NG (Navitor) Valve and FlexNav™ Delivery System; Navitor Titan Valve (35mm) Valve and Large FlexNav™ Delivery System · For: Symptomatic Severe Aortic Stenosis
Sites: Los Angeles, California; Thousand Oaks, California; Washington D.C., District of Columbia · 28 sites in all
Abbott Medical DevicesPublic (ABT)
NCT05171712 · 30 participants · Start May 6, 2022 · Primary completion Dec 21, 2024
Device: Transcatheter Aortic Valve Replacement · For: Aortic Valve Stenosis; Aortic Valve Failure; Aortic Insufficiency and 1 more
Sites: Chennai, India; Gūrgaon, India; Jaipur, India · 6 sites in all
- Portico Re-sheathable Transcatheter Aortic Valve System US IDE TrialPivotal-lookingActive, not recruiting
Abbott Medical DevicesPublic (ABT)
NCT02000115 · 1,242 participants · Start May 2014 · Primary completion Oct 2019
Device: Portico transcatheter aortic valve; Commercially available transcatheter aortic valve · For: Aortic Valve Stenosis
Sites: Birmingham, Alabama; Phoenix, Arizona; Concord, California · 70 sites in all
9 more trials with a free account
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "Portico", and for the whole product code for context.
This brand
518 reports: 67 malfunction, 386 injury, 65 death
Whole product code NPT
77,669 reports: 12,243 malfunction, 57,723 injury, 7,693 death
Newest reports for this brand
- Portico Transcatheter Aortic ValveMalfunction
2135147-2026-06061 · Received Sep 9, 2026 · Event dated Jan 1, 2010
Device type: Aortic Valve, Prosthesis, Percutaneously Delivered (NPT)
Device problem as coded: Patient-Device Incompatibility
Patient problem as coded: No Clinical Signs, Symptoms or Conditions
2135147-2026-06062 · Received Sep 9, 2026 · Event dated Jan 1, 2010
Device type: Aortic Valve, Prosthesis, Percutaneously Delivered (NPT)
Device problem as coded: Adverse Event Without Identified Device or Use Problem
Patient problem as coded: Atrial Fibrillation; Stroke/CVA; Endocarditis; Hematoma; Unspecified Infection; Renal Failure; Pseudoaneurysm; Pericardial Effusion; Aortic Valve Insufficiency/ Regurgitation
2135147-2026-05812 · Received Aug 25, 2026 · Event dated Dec 1, 2017
Device type: Aortic Valve, Prosthesis, Percutaneously Delivered (NPT)
Device problem as coded: Off-Label Use
Patient problem as coded: Stroke/CVA; Hemorrhage/Blood Loss/Bleeding; Renal Failure; Cardiac Tamponade; Pericardial Effusion; Aortic Valve Insufficiency/ Regurgitation; Coronary obstruction/occlusion
2 more reports with a free account
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
- Abbott Navitor Titan, Vision Technology, Transcatheter Aortic Heart Valve, 35 mm, NVRO-35, SterileOpen, Classified
Z-0491-2025 · Started Oct 17, 2024 · Posted by FDA Nov 20, 2024
Reason given: A manufacturing error resulting in acceptance of valves with a leaflet deflection value that was outside of established specifications. This could potentially affect long-term durability of the impacted valve and/or cause potential valve failure.
Cause as FDA categorized it: Under Investigation by firm · Device type: Aortic Valve, Prosthesis, Percutaneously Delivered (NPT)
Z-0492-2025 · Started Oct 17, 2024 · Posted by FDA Nov 20, 2024
Reason given: A manufacturing error resulting in acceptance of valves with a leaflet deflection value that was outside of established specifications. This could potentially affect long-term durability of the impacted valve and/or cause potential valve failure.
Cause as FDA categorized it: Under Investigation by firm · Device type: Aortic Valve, Prosthesis, Percutaneously Delivered (NPT)
- Abbot Navitor, Vision Technology, Transcatheter Aortic Heart Valve, 29 mm, NVRO-29, SterileOpen, Classified
Z-0493-2025 · Started Oct 17, 2024 · Posted by FDA Nov 20, 2024
Reason given: A manufacturing error resulting in acceptance of valves with a leaflet deflection value that was outside of established specifications. This could potentially affect long-term durability of the impacted valve and/or cause potential valve failure.
Cause as FDA categorized it: Under Investigation by firm · Device type: Aortic Valve, Prosthesis, Percutaneously Delivered (NPT)
2 more recall records with a free account
Published research
The most relevant PubMed records for "Portico"[tiab]. The summary above synthesizes these.
- The Promise of Portico.
Mavromatis K · JACC Cardiovasc Interv · 2017Editorial, Comment
- One-Year Results of the Portico Transcatheter Aortic Heart Valve Using the Next-Generation FlexNav Delivery System.
Fontana GP, Bedogni F, Groh M, et al. · J Soc Cardiovasc Angiogr Interv · 2023
- 30-Day Outcomes With the Portico Transcatheter Heart Valve: Insights From a Multi-Centre Australian Observational Study.
Camuglia AC, Cole CMW, Boyne N, et al. · Heart Lung Circ · 2023Observational Study, Multicenter Study
- Early clinical outcomes of Portico and Edwards Sapien 3 valve prosthesis in transcatheter aortic valve replacement: propensity-matched analysis.
Primessnig U, Wiedenhofer JM, Trippel TD, et al. · Front Cardiovasc Med · 2024
- The Portico transcatheter aortic valve for the treatment of severe aortic stenosis.
Taramasso M, Miura M, Gavazzoni M, et al. · Future Cardiol · 2019Review
- PORTICO: First Randomized Controlled Trial of Vasomodulator Therapy in Portopulmonary Hypertension.
Raevens S, Fallon MB · Hepatology · 2020Comment
- 30-Day Clinical Outcomes of a Self-Expanding Transcatheter Aortic Valve: The International PORTICO NG Study.
Reardon MJ, Chehab B, Smith D, et al. · JACC Cardiovasc Interv · 2023Multicenter Study, Research Support, Non-U.S. Gov't
- In-hospital outcomes of Portico transcatheter aortic valve replacement with the FlexNav as compared to the first-generation delivery system.
Rigattieri S, Marino G, Giovannelli F, et al. · Postepy Kardiol Interwencyjnej · 2023
- Comparative one-month safety and effectiveness of five leading new-generation devices for transcatheter aortic valve implantation.
Giordano A, Corcione N, Ferraro P, et al. · Sci Rep · 2019Comparative Study, Research Support, Non-U.S. Gov't
- Self-expanding Portico Valve Versus Balloon-expandable SAPIEN XT Valve in Patients With Small Aortic Annuli: Comparison of Hemodynamic Performance.
Del Trigo M, Dahou A, Webb JG, et al. · Rev Esp Cardiol (Engl Ed) · 2016Comparative Study
- Transcatheter Aortic Valve Implantation with the Portico Valve: 2-Year Outcomes of a Multicenter, Real-World Registry.
Didagelos M, Ninios V, Kakderis C, et al. · Life (Basel) · 2023
- Procedural safety of transcatheter aortic valve replacement with Portico valve: a systematic review.
Jaiswal V, Wajid Z, Suresh V, et al. · Int J Surg · 2023Systematic Review
Other devices of this type
Also filed under product code NPT.
- Sapien 3 Transcatheter Heart Valve and AccessoriesEdwards Lifesciences, LLC · PMA 2025
- Medtronic CoreValve Evolut R SystemMedtronic, Inc. · PMA 2022
- Edwards SAPIEN XT Transcatheter Heart ValveEdwards Lifesciences, LLC · PMA 2020
- Edwards SAPIEN 3 Ultra RESILIA Transcatheter Heart ValveEdwards Lifesciences, LLC · PMA 2026
- Medtronic CoreValve SystemMedtronic, Inc. · PMA 2023
- Edwards Sapien Transcatheter Heart Valve and Transfemoral and Transapical AccessoriesEdwards Lifesciences, LLC · PMA 2013
- Navitor Transcatheter Aortic Valve Implantation SystemAbbott Medical · PMA 2026
- Trilogy Transcatheter Heart Valve SystemJenaValve Technology, Inc. · PMA 2026
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.